Hemab Therapeutics (COAG)
Develops preventive therapies for rare bleeding and coagulation disorders.
Something off on this page? Send us feedback.
Develops preventive therapies for serious coagulation disorders, with a clinical pipeline in rare platelet and coagulation disorders and von Willebrand disease. The pre-revenue company has no approved products and funds R&D through equity and earlier convertible debt; future revenue could come from product sales, collaboration payments, or license payments.
Develops preventive therapies for serious coagulation disorders that lack adequate prophylaxis. The pipeline spans rare platelet and coagulation disorders, von Willebrand disease, and heavy menstrual bleeding, applying antibodies, peptides, and oligonucleotides selected by disease need rather than a single technology platform.
Sutacimig, a subcutaneous bispecific antibody, is the most advanced program for Glanzmann thrombasthenia and Factor VII deficiency. HMB-002 is an antibody for von Willebrand disease, while HMB-003 is a preclinical peptide directed at heavy menstrual bleeding and other bleeding settings.
Operates from Cambridge and Copenhagen with no approved products, product-sales revenue, manufacturing facilities, or commercial organization. Clinical progress depends on rare-disease enrollment, regulatory acceptance, external manufacturers, licensed intellectual property, and future financing.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 12, 2026 | Wedbush | Reiterate | Outperform | $55 | $64 |
| Aug 11, 2026 | H.C. Wainwright | Reiterate | Buy | $52 | $60 |
| Jul 13, 2026 | Jefferies | Reiterate | Buy | $39 | $47 |
| Jul 13, 2026 | Wedbush | Reiterate | Outperform | $42 | $55 |
| Jul 13, 2026 | H.C. Wainwright | Reiterate | Buy | $40 | $52 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $457.5M · Total debt $1.0M · Total assets $467.8M · Shareholders' equity $454.3M
- Revenue
- $0
- Operating income
- −$26.1M
- Net income
- −$24.2M
No dividends on record.
| Institutions56 holders · as of Jun 30, 2026 | 77.70% | 36.29M shares | |
| Otherremainder | 22.30% | 10.41M shares |
46.71M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 16.72% | 7.81M | 13Fas of Jun 30, 2026 |
Novo Holdings A/SInstitution | 8.95% | 4.18M | 13Fas of Jun 30, 2026 |
FMR LLCInstitution | 7.92% | 3.70M | 13Fas of Jun 30, 2026 |
Capital International InvestorsInstitution | 7.72% | 3.60M | 13Fas of Jun 30, 2026 |
Deep Track Capital, LPInstitution | 7.71% | 3.60M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Incyte
Late-stage monthly VWD prophylaxis versus HMB-002.
- Takeda (ADR)
Approved recombinant VWF prophylaxis alongside HMB-002.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Hemab Therapeutics | $44.11 | −1.21% | $2.09B | — | — | — | — |
| Incyte | $128.82 | +3.05% | $26.11B | 16.4 | 53.4 | 4.5 | +37.7% |
| Takeda (ADR) | $18.59 | +0.81% | $58.65B | 51.2 | 56.8 | 2.0 | +5.8% |
| Median | 33.8 | 55.1 | 3.3 | +21.7% |